Rapid progress in identifying biomarkers that are hallmarks of disease has increased
demand for high-performance detection technologies. Implementation of electrochemical …

Anticancer metallodrugs based on ruthenium and osmium are among the most investigated
and advanced non-platinum metallodrugs. Inorganic drug discovery with these agents has …

This review provides an introduction into the fascinating area of organometallic anticancer
compounds. Although the subject dates back many years, it has witnessed considerable …

Bioorganometallic chemistry is a rapidly develo** area of research. In recent years
organometallic compounds have provided a rich platform for the design of effective catalysts …

The small molecule anticancer agent cisplatin and its Pt (II) analogs carboplatin and
oxaliplatin are widely used to treat a variety of tumorigenic diseases. Despite their structural …

Highlights•Osmium complexes are promising anticancer agents.•In vitro assays revealed
antiproliferative activity in nanomolar concentrations.•New leads of osmium are well …

Recent work has shown that the chemical reactivity of osmium complexes can be finely
tuned by the choice of osmium oxidation state, the ligands (including C-and N-bound), and …

RuII (arene) complexes have been shown to be promising anticancer agents, capable of
overcoming major drawbacks of currently used chemotherapeutics. We have synthesized …

The advent of the clinically approved drug cisplatin started a new era in the design of
metallodrugs for cancer chemotherapy. However, to date, there has not been much success …

Hydroxypyridinones (HPs) are a family of N-heterocyclic core chelators which, based on
their specific metal-coordination, easy manipulation/derivatization and biocompatibility, have …